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ABSTRACT
Objective: The objective of the study was to monitor the adverse drug reactions (A.D.Rs.) associated with antihypertensive drugs.
Methods: All patients coming to the department with blood pressure systolic above 120 mmHg and diastolic above 90 mmHg and prescribed 
hypertensives will be screened for the study.
Results and Discussion: A total of 136 patients were observed during the study. Out of 136 patients, 23 (17%) A.D.Rs. were recorded. A study 
conducted by Ramesh et al. in the Indian capital reports that 22.3% of the patients experienced A.D.Rs.
Conclusion: Furthermore, any appearance of A.D.Rs. due to side effects of the drugs or due to bad control and patients non-compliance, it was treated 
mainly by decreasing the doses of the drugs, switching them to another active substance from the same pharmacological group, or by adding more 
active substances from different pharmacological groups in lower dosages to achieve the B.P goals.
Keywords: Adverse drug reaction, Monitoring, Hypertensive patients, Tertiary care center, India, Antihypertensive drugs.
INTRODUCTION
With the advent of newer medicines and evolution of the science, the 
numbers of treatment options for a single disease have increased. 
Therefore, every drug in the therapeutic area poses both benefits 
and potential threat for causing severe side effects. At times, these 
side effects are preventable and a timely reporting of same can avoid 
unwanted health hazards and save millions of lives. An initiative 
made in the same direction was to design and implement adverse 
event reporting systems by individual nations and then was adopted 
by the whole world either unanimously with global organizations 
or individualizing their own reporting system. Pharmacovigilance is 
entirely about monitoring adverse drug reactions (A.D.Rs.) and hence 
was defined as “The detection in the community of drug effects, usually 
adverse” [1].
Hypertension is a global public health issue. It is an important public 
health concern because of its associated morbidity, mortality, and 
economic impact on the society. Overall prevalence of hypertension 
in India reported 29.8% [2]. Nearly 1 billion people have high blood 
pressure (hypertension) globally; out of these, developing countries 
having two-thirds of patients. Premature deaths worldwide are mostly 
caused by hypertension and the disease is spontaneously growing with 
the estimation of 1.56 billion adults will be living with hypertension 
in 2025 [3]. India also facing substantial public health burden on 
cardiovascular health and health-care systems [4-6]. Approximately 
57% of all stroke deaths and 24% of all coronary heart disease 
deaths in India are directly by hypertension. Even the WHO also rates 
hypertension as one of the most important causes of premature deaths 
worldwide [5-10]. The present study is conducted to monitor the 
A.D.Rs. associated with antihypertensive drugs.
METHODS
All patients coming to the department with blood pressure systolic 
above 120 mmHg and diastolic above 90 mmHg and prescribed 
hypertensives will be screened for the study. Those who satisfy the 
inclusion criteria will be enrolled after taking written informed 
consent. Diagnosed patients of hypertension above the age of 18 years, 
and diagnosed with primary hypertension, will be included in the study.
The various study tools that will be used are the suspected ADR 
reporting form issued by Central Drugs Standard Control Organization 
under Pharmacovigilance Programme of India which will record all 
the information, such as name, age, sex, weight, other relevant history 
including pre-existing medical conditions, details of suspected ADRs, 
and details of suspected medications that the patients might be taking. 
A.D.Rs. reporting form records all the essential information regarding 
the adverse effects: The onset and severity of the A.D.R. experienced, 
the impact of A.D.Rs. on the treatment and work capacity of the patient, 
the drug(s) involved, the date of starting the suspected drugs, and the 
date of reporting of the A.D.Rs. Causality assessment will be done using 
Naranjo’s causality assessment scale [11].
Data management and analysis
Data will be aggregated according to disease profile and other relevant 
information required for the study. Causality assessment was done 
using Naranjo’s causality assessment scale.
For patients on antihypertensive treatment
Inclusion criteria
The following criteria were included in the study:
•	 Newly diagnosed patients of hypertension with blood pressure above 
120/90 mm Hg
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•	 Patients with age more than 18 years
•	 Patients of either sex
•	 Patients having baseline (pre-treatment) biochemical parameters 
other than blood sugar (i.e., liver function test and kidney function 
test) within normal range
•	 Patients having no associated comorbidities
Exclusion criteria
The following criteria were excluded from the study:
•	 Patients who were unwilling to participate and did not give consent 
in the study
•	 Patients who were unable to give interview
•	 Patients with incomplete medical records
•	 Patients with chronic liver disease such as cirrhosis, chronic hepatitis, 
and acute viral hepatitis
•	 Terminally ill patients
•	 Patients with concurrent major psychiatric illness and/or concurrent 
major medical illnesses.
Naranjo’s causality assessment scale
The Naranjo’s criteria classify the probability that an adverse event is 
related to drug therapy based on a list of weighted questions, which 
examine factors such as the temporal association of drug administration 
and event occurrence, alternative causes for the event, drug levels, 
dose–response relationships, and previous patient experience with the 
medication.
The A.D.Rs. are assigned to a probability category from the total score 
as follows: 
Definite if the overall score is 9 or greater, probable for a score of 5–8, 
possible for 1–4, and doubtful if the score is 0.
The Naranjo’s criteria do not take into account drug-drug interactions. 
Drugs are evaluated individually for causality, and points deducted 
if another factor may have resulted in the adverse event, thereby 
weakening the causal association.
Statistical analysis
Categorical variables will be presented in number and percentage (%). 
Qualitative variables will be compared using Chi-square test/Fisher’s 
exact test as appropriate. p<0.05 will be considered statistically 
significant. Statistical analysis was performed using GraphPad 
QuickCalcs software available online at http://graphpad.com/
quickcalcs/. The data will be entered into MS EXCEL spreadsheet and 
analysis will be done using Statistical Package for the Social Sciences 
(SPSS) version 21.0.
RESULTS
The present study was an open and non-comparative, based on 
a questionnaire (A.D.R. monitoring form) drafted according to 
Naranjo’s A.D.R. monitoring guidelines, which included data relating to 
patient demographic details (age, sex, height, weight, and body mass 
index [BMI]), medical history, present drug treatment, description, 
assessment, and treatment of A.D.Rs. The study protocol was approved 
by Institutional Medical Ethics Committee, Rama Medical College 
and Research Centre, Kanpur, U.P. The present study was conducted 
between June 01, 2018 and November 30, 2018 by attending the 
medicine OPD on a daily basis. A total of 23 A.D.Rs. were observed in 
136 patients during the study.
A.D.R. monitoring of antihypertensive medication
Twenty-three A.D.Rs. were observed in 136 patients of mean age 
49.6±12 years; mean BMI 25.7±8.1 kg/m2. A higher percentage of 
A.D.Rs. occurred in males (52%). A total of 7 (31.8%) were observed 
in the patient age group of 41–50 years, followed by 6 (27.2%) in 
31–40 years, 5 (22.7%) in 51–60 years, and 2 and 3 A.D.Rs. in each of 
61–70 years and >70 years age groups.
Only two A.D.Rs. were observed in hypertensive patients suffering 
from concomitant disease (one each with diabetes mellitus and 
asthma). Combination therapy was associated with significantly high 
occurrence (p<0.05) of A.D.Rs., with a total of 16 (69.7%) as compared 
to monotherapy (n=7, 30.43%).
Furthermore, most patients had an experience of ADRs due to 
pharmacotherapy. More specific 72% of study population had an 
experience of one A.D.R., 18% had an experience of two A.D.Rs., and 
only 8% had experience of three A.D.Rs. (Fig. 1).
On the causality scale of Naranjo’s, 7 (30%) A.D.Rs. were classified 
probable, 13 (56%) possible, 1 (4.3%) definite, and 2 (13 %) doubtful 
(Fig. 2).
In our study, we found that calcium channel blockers (CCBs) are the 
most common groups of drugs to treat the hypertensive patients, then 
followed by beta-blockers and diuretics. CCBs accounted for 34.78% 
of total A.D.Rs. followed by beta-blockers (26.08%), angiotensin-
converting enzyme (ACE) inhibitors (17.39%), angiotensin receptor 
blockers (ARBs) (8.69%), and diuretics (4.3%).
Among individual drugs, amlodipine was the drug associated with 
maximum A.D.Rs., including pedal edema, general edema, giddiness, 
headache, and abdominal pain. Beta-blockers, namely, atenolol, 
metoprolol, and nebivolol were the next which reported A.D.Rs. such as 
hypotension, headache, impotence, and bronchospasm. ACE inhibitors 
and ARBs were associated with dry cough, taste alteration. Patients on 
diuretics reported least number of A.D.Rs. (Table 1). Furthermore, 5% 
of patients with other concomitant disease like dyslipidemia showed 
myalgia and increased CPK levels due to statins which was an additive 
to antihypertensive therapy, and the rest of A.D.Rs., each of them 
accounts 1% or less of the total study population.
The A.D.Rs. associated with central nervous system were found to 
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Fig. 2: The bar graph shows % of adverse drug reaction classified 
as possible, probable, unlikely and unclassified according to 












Fig. 1: The pie graph shows % frequency of adverse drug reaction 
(A.D.R.) reported per person where 100% is the total number of 
patients on antihypertensive who experienced A.D.Rs
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gastrointestinal A.D.Rs. (abdominal pain, constipation, and diarrhea), 
and respiratory system (Fig. 3).
The most common systems associated with A.D.Rs. in our study 
were the central nervous system, followed by cardiovascular system, 
gastrointestinal system, and respiratory and dermatological system 
(Fig. 4).
DISCUSSION
We studied 136 patients on antihypertensive medications and observed 
the incidence and pattern of ADRs in them. Out of 136 patients, 23 (17%) 
A.D.Rs. were recorded. A study conducted by Ramesh et al. [12-15] 
in the Indian capital reports that 22.3% of the patients experienced 
A.D.Rs. Another report on A.D.R. monitoring in North India by Garg and 
Singhal [15] mentions that 5.9% of all visits to the medical department 
are drug related, and A.D.Rs. accounted for 45% of events which depicts 
a higher percentage of A.D.Rs.
According to the Naranjo’s causality scale, 30% (7) of cases were 
classified probable, 56% (13) of cases possible, 13% of cases were 
doubtful, and 4% of cases fell in the definite category. This result is 
similar to studies done by Khurshid [15,16].
Out of 23 A.D.Rs. recorded in antihypertensive patients, 34.78% (8 out 
of 23) was observed in patients prescribed CCBs, 26.08% (7 out of 23) 
in patients prescribed on beta-blockers, 17.39% (4 out of 23) by ACE 
inhibitors, 8.69% (2 out of 23) by ARBs, and 1 out of 23 that is 4.35 by 
diuretics is responsible for causing A.D.R.
A.D.Rs. of particular drugs can influence compliance of antihypertensive 
agents, because they frequently decrease quality of life, which is 
important by asymptomatic disease. Therefore, we were looking for 
physicians notice in health documentation regarding A.D.Rs.
Any appearance of A.D.Rs. due to side effects of the drugs or due to 
bad control and patient’s non-compliance (refuse to follow doctors’ 
instructions or forgetting to take the medicine), it was treated mainly 
by decreasing the doses of the drugs, switching them to another 
Table 1: % of A.D.R. experienced by patients receiving respective classes of antihypertensive drugs and other concomitant drugs if 
any (figure in bracket denotes the total number of episodes reported due to a particular class of drug)
Therapeutics class of suspected antihypertensive medications and adverse drug reactions.
Therapeutic class of 
drug
Drugs Suspected A.D.R. Total number of patients with A.D.R.
(No. of patients receiving the drug)
Percentage of A.D.R.



























Hypotension (1) 1 4.3%








Other vitamin preparation 
or antioxidant





Analgesics Aceclofenac Swelling of face (1) 1





A.D.Rs. mentioned in the second section of the study
A.D.R.: Adverse drug reaction, ARBs: Angiotensin receptor blockers, ACEI: Angiotensin-converting enzyme inhibitor




Metabolic disorders Frequency of ADR
Fig. 4: The graph depicts system wise involvement of adverse drug 
reactions (A.D.Rs) according to the frequency of category of A.D.R
Fig. 3: The graph depicts symptom wise involvement of adverse 
drug reactions (A.D.Rs.) according to the frequency of category of 
A.D.R
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active substance from the same pharmacological group (depending 
on patients’ tolerability), or by adding more active substances from 
different pharmacological groups in lower dosages and combined 
pills, to achieve the B.P. goals. Furthermore, in case of patients’ non-
compliance, the use of combined slow release regimens it was preferred.
Among the different A.D.Rs. reported from different systems due to 
antihypertensive medications, most of the A.D.Rs. were of central 
nervous system origin, followed by cardiovascular system, and 
gastrointestinal and respiratory system.
CONCLUSION
Out of 120 patients, 23 patients developed A.D.Rs. The age group 51–60 
years being more vulnerable showed higher incidence and outnumbered 
the patients in other group who developed A.D.Rs. As compared to 
females, there were more males with A.D.Rs. because male constituted 
more of our sample population. Out of 23 A.D.Rs. recorded, percent 
A.D.R. frequency was seen maximum in patients prescribed CCBs that is 
34.78%. Maximum number of the patients developing A.D.Rs. came up 
with adverse effects related to central nervous system such as headache 
and giddiness. On assessment of causality through Naranjo’s algorithm, 
maximum of the ADRs have been categorized under “possible” which 
is being followed by category of “probable” (56%; 30%). Furthermore, 
the most common comorbidities along with hypertension were 
dyslipidemia and C.H.D, as well as the most frequently used drug 
groups were anti-hyperlipidemic, BBs, anticoagulant-antiplatelet, and 
ARBs. More specific from the point of active substances atorvastatin, 
metoprolol, aspirin, and telmisartan in different combinations, doses, 
and dosage schemes seems to be the most favorable prescribed drugs.
Furthermore, any appearance of A.D.Rs. due to side effects of the drugs 
or due to bad control and patients non-compliance, it was treated 
mainly by decreasing the doses of the drugs, switching them to another 
active substance from the same pharmacological group, or by adding 
more active substances from different pharmacological groups in lower 
dosages to achieve the B.P. goals.
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